[
  {
    "ts": null,
    "headline": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
    "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
    "url": "https://finnhub.io/api/news?id=0222852a318b73255d22e3c6239c346281539f73dd30a652b065167793d1eec2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768417556,
      "headline": "JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries",
      "id": 138114828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.",
      "url": "https://finnhub.io/api/news?id=0222852a318b73255d22e3c6239c346281539f73dd30a652b065167793d1eec2"
    }
  }
]